Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tadalafil is a selective phosphodiesterase 5 (PDE5) inhibitor used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). It works by blocking the enzyme PDE5, leading to increased levels of cyclic guanosine monophosphate (cGMP), which causes smooth muscle relaxation and increased blood flow in specific tissues. For ED, this results in improved erectile function; for BPH, it relaxes muscles in the prostate and bladder; for PAH, it relaxes blood vessels in the lungs to lower blood pressure. Tadalafil was originally developed by ICOS Corporation and later co-developed with Eli Lilly. It is marketed under several brand names including Cialis for ED/BPH and Adcirca for PAH[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tadalafil.